RMD · NYSE · Healthcare
ResMed Inc. (RMD) — Rank #142 by gross profitability (GP/assets 0.38) · ROE 23.1% · Piotroski F-Score 7 / 9.
As-of 2026-10-30 · CIK 0000943819 · all metrics point-in-time as of the filing date.
About
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally.
Show moreShow less
It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc.
was founded in 1989 and is headquartered in San Diego, California.
- Industry
- Medical Instruments & Supplies
- Sector
- Healthcare
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- June 30
- Website
- resmed.com
Company Snapshot
P/E and reverse DCF are the primary valuation lenses at this stage.
Market Cap
$32.83B
P/E (annual)
—
P/S (annual)
5.8
P/B
5.0
P/OCF (annual)
18.2
Shareholder Yield
1.9%
Employees
11,370
Industry
Medical Instruments & Supplies
Exchange
NYSE
12/12
Flags passed
RMD passes 12/12 quality flags
- PASSGross margin holding
- PASSDilution within 2%
- PASSFCF not negative from investment
- PASSDisclosure consistent
- PASSRevenue not declining
- PASSOperating margin holding
- PASSFree cash flow intact
- PASSPasses safety gate
- PASSBalance sheet stable
- PASSNo competitive retreat
- PASSSBC not compressing margin
- PASSNo valuation convergence
Strengths Revenue growth accelerating · Operating leverage expanding
A count of the 12 warning flags that could be evaluated. Unweighted: colour follows the worst flag.
Quality Profile
Profitability
1/1 passSafety
1/1 passCash Flow
3/3 passGrowth
2/2 passFCF yield, shareholder yield, and buyback activity are the primary reads at this stage.
Profitability
Does it make money well?
No warning flags · GP/assets 53rd percentile of 20 SIC 3841 peers
Gross profitability (GP / assets)
0.38
Primary signal (Novy-Marx).
53rd pctl of 20 SIC 3841 peers
Return on equity
23.1%
Gross margin
61.1%
37th pctl of 20 SIC 3841 peers
Revenue growth (YoY)
9.9%
Gross margin improving
Margin trend vs prior year.
Operating Leverage
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Revenue vs COGS | ||||
| Revenue vs OpEx | ||||
| Op. Income vs Revenue |
Growth
Revenue CAGR (3Y)
10.2%
Revenue CAGR (5Y)
12.1%
Earnings CAGR (3Y)
19.3%
FCF CAGR (3Y)
42.2%
Cash Flow Health
Is the cash real?
No warning flags · FCF 8% above net income
Free cash flow
$1.65B
Operating cash flow minus capex.
Positive free cash flow
FCF vs net income
8.3%
(FCF − net income) ÷ |net income|. Positive: cash above earnings. Negative: below.
FCF not below net income
Fails when free cash flow is below net income (yellow flag).
Accruals healthy
Cash-backed earnings.
SBC / revenue
1.8%
Stock-based comp intensity.
Balance Sheet Strength
Can it survive a storm?
No warning flags · net cash $809.87M, F-Score 7/9
Balance-sheet safety
Composite anti-fragile check.
Debt / equity
0.36
5th of 19 SIC 3841 peers (best = lowest)
Current ratio
3.10×
63rd pctl of 20 SIC 3841 peers
Quick ratio
1.80×
Net cash
$809.87M
Cash & equivalents minus total debt.
Piotroski F-Score
7 / 9
Fundamental-strength score (0-9).
Valuation
Is the price reasonable?
No warning flags
Valuation History
Current multiple vs historical range at each filing date. Band spans 25th-75th percentile.
P / E
Price / diluted EPS
P / S
Price / revenue per share
P / B
Price / book value per share
P / GP
Price / gross profit per share
P / FCF
Price / free cash flow per share
Dividend safety
Composite score
4.2 / 5
Capital allocation quality
Composite score
4.2 / 5
Lifecycle Phase History
Price History
Source filings on SEC EDGAR: 10-K annual reports · 10-Q quarterly reports